Navigation Links
A new radiation therapy treatment developed for head and neck cancer patients
Date:8/17/2007

Most head-and-neck cancers that recur locally after prior full-dose conventional radiation therapy respond to Boron Neutron Capture Therapy (BNCT). These results were obtained in a Phase I/II study at the Helsinki University Hospital, Finland. The scientific director of the research program, professor Heikki Joensuu, University of Helsinki, considers the results clinically significant and very interesting. They open a new field for BNCT, since thus far BNCT has been evaluated only in the treatment of some brain tumours.

The follow-up results of 12 patients diagnosed with cancer of the head-and-neck and treated in a prospective clinical trial were reported in the International Journal of Radiation Oncology, Biology & Physics (online version available: www.redjournal.org). All patients had cancer of the head-and-neck that had recurred locally after surgery and conventional radiation therapy. Ten out of the 12 patients had substantial tumour shrinkage following BNCT, and in 7 cases the tumour disappeared completely. Adverse effects of treatment were moderate and resembled those of conventional radiation therapy.

The study has been expanded, and up to 30 subjects will now be allowed to enter the study protocol.

Boron neutron capture therapy (BNCT) is a form of targeted radiation treatment for cancer. It is still considered experimental. In this method a boron-containing compound (boronophenylalanine) is first infused into a peripheral vein, following which the compound accumulates in cancer tissue. Cancer is subsequently irradiated with neutrons obtained from a nuclear reactor, which causes boron atoms to split within the cancerous tissue as a result from a boron neutron capture reaction. The resulting smaller particles cause a large radiation effect within the tumour tissue, which destroys cancer cells.

The technique allows targeting of a high dosage of radiation to the tumour while allowing sparing of the adjacent normal tissues from the highest doses of radiation. Boron-mediated targeting of radiation allows treatment of patients who can no longer be treated with conventional radiation therapy. BNCT is administered as single one-day treatment that may be repeated.

The study was sponsored by Boneca Corporation, the spinoff company operating on the medical campus of the Helsinki University and the University Central Hospital (www.boneca.fi). The treatments are carried out in collaboration with the Department of Oncology, Helsinki University Central Hospital, at the BNCT facility constructed at the VTT research nuclear reactor site located at Otaniemi, Espoo. The neutron radiation used in the treatment is provided by VTT.

Boneca Corporations clinical research program includes also a phase I/II study that evaluates BNCT in the treatment of primary glioblastoma (a highly malignant brain tumour) and another clinical trial that assesses safety and efficacy of BNCT in the treatment of glioblastomas and anaplastic astrocytomas (a type of brain tumour) that have recurred after conventional radiation therapy.

Our plan is to investigate BNCT in the treatment of cancers located elsewhere in the body that cannot be effectively managed by any known treatment, says professor Heikki Joensuu.

The current treatment is a result of a long period of research, a proof of academic expertise, and a model for effective collaboration between Helsinki University Central Hospital, University of Helsinki, VTT Technical Research Centre of Finland, and the company, says Boneca Corporations managing director Markku Pohjola.


'/>"/>

Contact: Professor Heikki Joensuu
heikki.joensuu@hus.fi
358-947-173-208
University of Helsinki
Source:Eurekalert

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Gene therapy may protect normal tissues during radiation retreatment for lung cancer
4. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
5. Radiation-killed bacteria vaccine induces broad immune response in mice
6. Radiation-armed robot rapidly destroys human lung tumors
7. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
8. Gene therapy protects mice from the effects of whole-body irradiation
9. Cancer stem cells linked to radiation resistance
10. Mars mission Risk 29: Scientists research ways to reduce radiation-induced brain damage
11. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
(Date:3/22/2017)... ... 2017 , ... Researchers face a fundamental challenge as they ... tissues, bones, even whole organs to implant in people to treat disease or ... the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t fabricate ...
(Date:3/22/2017)... , March 22, 2017   iSpecimen ®, ... that Doctors Pathology Service (DPS), a full-service ... the United States , has joined ... Health Information Network (DHIN) to make human biospecimens ... The novel program, announced in 2015 as a ...
(Date:3/22/2017)... Pa. , March 22, 2017 /PRNewswire/ ... global independent provider of product and service ... today that it has acquired EPL Archives, ... supports customers across the entire regulated product ... archive sample, document storage and ancillary services. ...
Breaking Biology Technology: